Literature DB >> 31651976

Early Effects of Cyclophosphamide, Methotrexate, and 5-Fluorouracil on Neuronal Morphology and Hippocampal-Dependent Behavior in a Murine Model.

Julie E Anderson1,2, Madison Trujillo1,2, Taylor McElroy1,2, Thomas Groves1,2,3, Tyler Alexander1,2, Frederico Kiffer1,2, Antiño R Allen1,2,3.   

Abstract

Breast cancer (BC) is the most common cancer among women. Fortunately, BC survival rates have increased because the implementation of adjuvant chemotherapy leading to a growing population of survivors. However, chemotherapy-induced cognitive impairments (CICIs) affect up to 75% of BC survivors and may be driven by inflammation and oxidative stress. Chemotherapy-induced cognitive impairments can persist 20 years and hinder survivors' quality of life. To identify early effects of CMF administration in mice, we chose to evaluate adult female mice at 2-week postchemotherapy. Mice received weekly IP administration of CMF (or saline) for 4 weeks, completed behavioral testing, and were sacrificed 2 weeks following their final CMF injection. Behavioral results indicated long-term memory (LTM) impairments postchemotherapy, but did not reveal short-term memory deficits. Dendritic morphology and spine data found increases in overall spine density within CA1 basal and CA3 basal dendrites, but no changes in DG, CA1 apical, or CA3 apical dendrites. Further analysis revealed decreases in arborization across the hippocampus (DG, CA1 apical and basal, CA3 apical and basal). These physiological changes within the hippocampus correlate with our behavioral data indicating LTM impairments following CMF administration in female mice 2-week postchemotherapy. Hippocampal cytokine analysis identified decreases in IL-1α, IL-1β, IL-3, IL-10, and TNF-α levels.
© The Author(s) 2019. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.

Entities:  

Keywords:  5-fluorouracil; cognition; cyclophosphamide; hippocampus; methotrexate

Mesh:

Substances:

Year:  2020        PMID: 31651976      PMCID: PMC8204947          DOI: 10.1093/toxsci/kfz213

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  99 in total

1.  Rapid dendritic morphogenesis in CA1 hippocampal dendrites induced by synaptic activity.

Authors:  M Maletic-Savatic; R Malinow; K Svoboda
Journal:  Science       Date:  1999-03-19       Impact factor: 47.728

Review 2.  Central nervous system toxicities of chemotherapeutic agents.

Authors:  Parvin F Peddi; Srinivas Peddi; Edgardo S Santos; Daniel Morgensztern
Journal:  Expert Rev Anticancer Ther       Date:  2014-04-21       Impact factor: 4.512

Review 3.  The effect of systemic chemotherapy on neurogenesis, plasticity and memory.

Authors:  Peter Wigmore
Journal:  Curr Top Behav Neurosci       Date:  2013

Review 4.  Branching out: mechanisms of dendritic arborization.

Authors:  Yuh-Nung Jan; Lily Yeh Jan
Journal:  Nat Rev Neurosci       Date:  2010-05       Impact factor: 34.870

5.  Cognitive impairments caused by oxaliplatin and 5-fluorouracil chemotherapy are ameliorated by physical activity.

Authors:  Joanna E Fardell; Janette Vardy; Jeanette D Shah; Ian N Johnston
Journal:  Psychopharmacology (Berl)       Date:  2011-09-06       Impact factor: 4.530

Review 6.  Cyclophosphamide and cancer: golden anniversary.

Authors:  Ashkan Emadi; Richard J Jones; Robert A Brodsky
Journal:  Nat Rev Clin Oncol       Date:  2009-09-29       Impact factor: 66.675

7.  Long-lasting suppression of hippocampal cell proliferation and impaired cognitive performance by methotrexate in the rat.

Authors:  Riejanne Seigers; Sanne B Schagen; Wieteke Beerling; Willem Boogerd; Olaf van Tellingen; Frits S A M van Dam; Jaap M Koolhaas; Bauke Buwalda
Journal:  Behav Brain Res       Date:  2007-08-10       Impact factor: 3.332

Review 8.  Clinical pharmacology of 5-fluorouracil.

Authors:  R B Diasio; B E Harris
Journal:  Clin Pharmacokinet       Date:  1989-04       Impact factor: 6.447

9.  The birth of chemotherapy at Yale. Bicentennial lecture series: Surgery Grand Round.

Authors:  Panos Christakis
Journal:  Yale J Biol Med       Date:  2011-06

Review 10.  Cytokines as Biomarkers and Their Respective Clinical Cutoff Levels.

Authors:  Rebecca N Monastero; Srinivas Pentyala
Journal:  Int J Inflam       Date:  2017-04-09
View more
  5 in total

Review 1.  Chemobrain in Breast Cancer: Mechanisms, Clinical Manifestations, and Potential Interventions.

Authors:  Giovana R Onzi; Nathalia D'Agustini; Solange C Garcia; Silvia S Guterres; Paula R Pohlmann; Daniela D Rosa; Adriana R Pohlmann
Journal:  Drug Saf       Date:  2022-05-23       Impact factor: 5.606

2.  Cognitive impairment resulting from treatment with docetaxel, doxorubicin, and cyclophosphamide.

Authors:  Taurean Brown; Taylor McElroy; Pilar Simmons; Huddoy Walters; Fabio Ntagwabira; Jing Wang; Stephanie D Byrum; Antiño R Allen
Journal:  Brain Res       Date:  2021-03-08       Impact factor: 3.610

Review 3.  Implications of Breast Cancer Chemotherapy-Induced Inflammation on the Gut, Liver, and Central Nervous System.

Authors:  Taurean Brown; DeLawrence Sykes; Antiño R Allen
Journal:  Biomedicines       Date:  2021-02-13

Review 4.  Animal models of chemotherapy-induced cognitive decline in preclinical drug development.

Authors:  Jeena John; Manas Kinra; Jayesh Mudgal; G L Viswanatha; K Nandakumar
Journal:  Psychopharmacology (Berl)       Date:  2021-10-13       Impact factor: 4.415

5.  ADSC-Exosomes Alleviate MTX-induced Rat Neuronal Damage by Activating Nrf2-ARE Pathway.

Authors:  Tingting Huang; Hongfei Tong; Haixia Zhou; Juxiang Wang; Linglong Hu; Yao Wang; Zhen Huang
Journal:  J Mol Neurosci       Date:  2022-03-23       Impact factor: 2.866

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.